Jonathan Treherne
Président chez NeuroSolutions Ltd.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Kristian Strømgaard | M | - |
Avilex Pharma ApS
Avilex Pharma ApS Pharmaceuticals: MajorHealth Technology Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark. | 12 ans |
Francoise Barbira-Freedman | M | - |
Ampika Ltd.
Ampika Ltd. Drugstore ChainsRetail Trade Ampika Ltd. discovers and develops drugs. It develops consumer products and prescription drugs from plant-based compounds. Its products includes cardiovascular protection, anti-infectives, diabetes, oncology, dermatological conditions and neurological. The company was founded by Francoise Barbira Freedman, Margaret Adey, Paul Rodgers and Jonathan Mark Treherne in May 2003 and is headquartered in Cambridge, the United Kingdom. | 21 ans |
Andrew Hopkinson | M | - |
NuVision Biotherapies Ltd.
NuVision Biotherapies Ltd. Pharmaceuticals: MajorHealth Technology NuVision Biotherapies Ltd. commercializes biotherapies for treating ‘front of the eye’ disease and trauma. It offers Omnigen, an ‘off the shelf’, transportable biological matrix that can be used as an effective wound dressing for a range of indications including ocular surface indications. The firm also offers Tereo, a process that gently preserves the tissue such that it is stored in a dry state. The company was founded by Andrew Hopkinson in July 2014 and is headquartered in Nottingham, the United Kingdom. | 10 ans |
Jason Mundin | M | - |
Ubiquigent Ltd.
Ubiquigent Ltd. Miscellaneous Commercial ServicesCommercial Services Ubiquigent Ltd. develops reagents, kits, drug discovery assay development and compound profiling services to the academic and commercial life science research community worldwide. It focus; namely the ubiquitin, ubiquitin-like and integrated signalling systems. The company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery as well as with pharmaceutical and biotechnology company scientists undertaking ubiquitin system-focused drug discovery. Ubiquigent was founded by Jason Brown in 2009 and is headquartered in Dundee, the United Kingdom. | 9 ans |
Ray Hill | M | 79 |
Avilex Pharma ApS
Avilex Pharma ApS Pharmaceuticals: MajorHealth Technology Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark. | - |
Emily Anne Scraggs | M | 55 |
Talisman Therapeutics Ltd.
Talisman Therapeutics Ltd. BiotechnologyHealth Technology Talisman Therapeutics Ltd. is a human stem cell research and development company. The firm is committed for revolutionizing the discovery of treatments for Alzheimer’s disease. The company is headquartered in Cambridge, the United Kingdom. | - |
Roger Peter Teasdale | M | 57 |
NuVision Biotherapies Ltd.
NuVision Biotherapies Ltd. Pharmaceuticals: MajorHealth Technology NuVision Biotherapies Ltd. commercializes biotherapies for treating ‘front of the eye’ disease and trauma. It offers Omnigen, an ‘off the shelf’, transportable biological matrix that can be used as an effective wound dressing for a range of indications including ocular surface indications. The firm also offers Tereo, a process that gently preserves the tissue such that it is stored in a dry state. The company was founded by Andrew Hopkinson in July 2014 and is headquartered in Nottingham, the United Kingdom. | 6 ans |
Hamon Francis Fytton | M | 72 |
University of Kentucky
| 10 ans |
Frederick John Livesey | M | 54 |
Talisman Therapeutics Ltd.
Talisman Therapeutics Ltd. BiotechnologyHealth Technology Talisman Therapeutics Ltd. is a human stem cell research and development company. The firm is committed for revolutionizing the discovery of treatments for Alzheimer’s disease. The company is headquartered in Cambridge, the United Kingdom. | - |
Margaret Addy | M | - |
Ampika Ltd.
Ampika Ltd. Drugstore ChainsRetail Trade Ampika Ltd. discovers and develops drugs. It develops consumer products and prescription drugs from plant-based compounds. Its products includes cardiovascular protection, anti-infectives, diabetes, oncology, dermatological conditions and neurological. The company was founded by Francoise Barbira Freedman, Margaret Adey, Paul Rodgers and Jonathan Mark Treherne in May 2003 and is headquartered in Cambridge, the United Kingdom. | 21 ans |
Marjorie Sidhoum | M | - |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | 11 ans |
Kate Rowley | M | - |
Ubiquigent Ltd.
Ubiquigent Ltd. Miscellaneous Commercial ServicesCommercial Services Ubiquigent Ltd. develops reagents, kits, drug discovery assay development and compound profiling services to the academic and commercial life science research community worldwide. It focus; namely the ubiquitin, ubiquitin-like and integrated signalling systems. The company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery as well as with pharmaceutical and biotechnology company scientists undertaking ubiquitin system-focused drug discovery. Ubiquigent was founded by Jason Brown in 2009 and is headquartered in Dundee, the United Kingdom. | - |
Jenny Barnett | M | - |
Monument Therapeutics Ltd.
Monument Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Monument Therapeutics Ltd. is a British UK-based biotechnology company that focuses on bringing precision medicine to neuroscience drug development. The company is based in Bottisham, UK, and was founded in 2019. The company was formed as a spin-out from Cognition and has a mission to use precision medicine to develop therapeutic products for patients with substantial central nervous system indications and significant unmet medical needs. Monument Tx has a well-balanced pipeline that includes two lead programs, and proprietary biomarkers developed by the team allow for precise selection of patients most likely to benefit from treatment. The therapeutic products under development are novel formulations utilizing well-characterized technology. Jenny Barnett has been the CEO of the company since 2019. | 5 ans |
Abeer M. Al-Ghananeem | M | - |
University of Kentucky
| - |
Sylvie Ryckebusch | M | - |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | - |
George A. Digenis | M | - |
University of Kentucky
| - |
Arenal Del Adrian | M | - |
NuVision Biotherapies Ltd.
NuVision Biotherapies Ltd. Pharmaceuticals: MajorHealth Technology NuVision Biotherapies Ltd. commercializes biotherapies for treating ‘front of the eye’ disease and trauma. It offers Omnigen, an ‘off the shelf’, transportable biological matrix that can be used as an effective wound dressing for a range of indications including ocular surface indications. The firm also offers Tereo, a process that gently preserves the tissue such that it is stored in a dry state. The company was founded by Andrew Hopkinson in July 2014 and is headquartered in Nottingham, the United Kingdom. | 7 ans |
Jeffrey J. Waldal | M | 59 |
University of Kentucky
| - |
Douglas A. Boyd | M | - |
University of Kentucky
| 37 ans |
Da Yong Gao | M | 65 |
University of Kentucky
| 20 ans |
Dario Alessi | M | - |
Ubiquigent Ltd.
Ubiquigent Ltd. Miscellaneous Commercial ServicesCommercial Services Ubiquigent Ltd. develops reagents, kits, drug discovery assay development and compound profiling services to the academic and commercial life science research community worldwide. It focus; namely the ubiquitin, ubiquitin-like and integrated signalling systems. The company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery as well as with pharmaceutical and biotechnology company scientists undertaking ubiquitin system-focused drug discovery. Ubiquigent was founded by Jason Brown in 2009 and is headquartered in Dundee, the United Kingdom. | - |
Sheila Brothers | F | - |
University of Kentucky
| - |
Irina Voro | F | - |
University of Kentucky
| - |
Guy Le Houillier | M | - |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | - |
Patricia Zerr | F | - |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | - |
Nathalie Lenne | F | - |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | - |
Bryan Sunderland | M | - |
University of Kentucky
| - |
Cathy Black | F | - |
University of Kentucky
| - |
Anthony Donahue | M | - |
University of Kentucky
| - |
Brigitte Kieffer | F | - |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | - |
Morten Graugaard Doessing | M | - |
Avilex Pharma ApS
Avilex Pharma ApS Pharmaceuticals: MajorHealth Technology Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark. | - |
Carin Ingemarsdotter | M | 45 |
Spliceor Ltd.
Spliceor Ltd. BiotechnologyHealth Technology Spliceor Ltd. is a British company founded in 2020 that specializes in gene therapies for aggressive cancers. The company is based in Cambridge, UK. The company's website is currently under construction, but more details are expected to follow. | 4 ans |
Andrew Michael Lever | M | 71 |
Spliceor Ltd.
Spliceor Ltd. BiotechnologyHealth Technology Spliceor Ltd. is a British company founded in 2020 that specializes in gene therapies for aggressive cancers. The company is based in Cambridge, UK. The company's website is currently under construction, but more details are expected to follow. | 4 ans |
Nathaniel Morris | M | 43 |
University of Kentucky
| - |
Bruce L. Walcott | M | - |
University of Kentucky
| - |
Esther Penni Black | M | - |
University of Kentucky
| - |
J. William Earle | M | - |
University of Kentucky
| 20 ans |
Roger W. Schipke | M | 87 |
University of Kentucky
| - |
Richard Bungay | M | 55 |
Monument Therapeutics Ltd.
Monument Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Monument Therapeutics Ltd. is a British UK-based biotechnology company that focuses on bringing precision medicine to neuroscience drug development. The company is based in Bottisham, UK, and was founded in 2019. The company was formed as a spin-out from Cognition and has a mission to use precision medicine to develop therapeutic products for patients with substantial central nervous system indications and significant unmet medical needs. Monument Tx has a well-balanced pipeline that includes two lead programs, and proprietary biomarkers developed by the team allow for precise selection of patients most likely to benefit from treatment. The therapeutic products under development are novel formulations utilizing well-characterized technology. Jenny Barnett has been the CEO of the company since 2019. | - |
Lawrence E. O'Connell | M | - |
University of Kentucky
| - |
Julian Gilbert | M | 63 |
Monument Therapeutics Ltd.
Monument Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Monument Therapeutics Ltd. is a British UK-based biotechnology company that focuses on bringing precision medicine to neuroscience drug development. The company is based in Bottisham, UK, and was founded in 2019. The company was formed as a spin-out from Cognition and has a mission to use precision medicine to develop therapeutic products for patients with substantial central nervous system indications and significant unmet medical needs. Monument Tx has a well-balanced pipeline that includes two lead programs, and proprietary biomarkers developed by the team allow for precise selection of patients most likely to benefit from treatment. The therapeutic products under development are novel formulations utilizing well-characterized technology. Jenny Barnett has been the CEO of the company since 2019. | 3 ans |
Woodford S. van Meter | M | 70 |
University of Kentucky
| - |
Bernard Daugeras | M | - |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | 16 ans |
Robert A. Lodder | M | 65 |
University of Kentucky
| - |
Russell J. Mumper | M | - |
University of Kentucky
| - |
Laurence Ede | M | 52 |
Ubiquigent Ltd.
Ubiquigent Ltd. Miscellaneous Commercial ServicesCommercial Services Ubiquigent Ltd. develops reagents, kits, drug discovery assay development and compound profiling services to the academic and commercial life science research community worldwide. It focus; namely the ubiquitin, ubiquitin-like and integrated signalling systems. The company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery as well as with pharmaceutical and biotechnology company scientists undertaking ubiquitin system-focused drug discovery. Ubiquigent was founded by Jason Brown in 2009 and is headquartered in Dundee, the United Kingdom. | - |
Daniel Tao | M | - |
University of Kentucky
| - |
Michel Ronc | M | 79 |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | 16 ans |
Audra L. Stinchcomb | M | - |
University of Kentucky
| 19 ans |
J. Zach Hilt | M | - |
University of Kentucky
| 20 ans |
Nanna Liebach Lüneborg | M | 49 |
Avilex Pharma ApS
Avilex Pharma ApS Pharmaceuticals: MajorHealth Technology Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark. | - |
Laura Douglas | F | 74 |
University of Kentucky
| - |
Stephan Schann | M | - |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | 16 ans |
Sébastien Groyer | M | 44 |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | 12 ans |
Christel Franchet | M | - |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | - |
Don Frazier | M | - |
University of Kentucky
| - |
Christine Riordan | M | 59 |
University of Kentucky
| 11 ans |
Ronda S. Beck | F | - |
University of Kentucky
| - |
Ron Eller | M | - |
University of Kentucky
| - |
Shiela S. Medina | F | - |
University of Kentucky
| - |
Jennifer Swanberg | F | - |
University of Kentucky
| - |
James W. Tracy | M | - |
University of Kentucky
| - |
Ian W. Ratcliffe | M | 63 |
Ubiquigent Ltd.
Ubiquigent Ltd. Miscellaneous Commercial ServicesCommercial Services Ubiquigent Ltd. develops reagents, kits, drug discovery assay development and compound profiling services to the academic and commercial life science research community worldwide. It focus; namely the ubiquitin, ubiquitin-like and integrated signalling systems. The company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery as well as with pharmaceutical and biotechnology company scientists undertaking ubiquitin system-focused drug discovery. Ubiquigent was founded by Jason Brown in 2009 and is headquartered in Dundee, the United Kingdom. | - |
Harvie Wilkinson | M | - |
University of Kentucky
| - |
Michael Salako | M | 44 |
Spliceor Ltd.
Spliceor Ltd. BiotechnologyHealth Technology Spliceor Ltd. is a British company founded in 2020 that specializes in gene therapies for aggressive cancers. The company is based in Cambridge, UK. The company's website is currently under construction, but more details are expected to follow. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Pascal Neuville | M | 60 |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | 16 ans |
Jason Brown | M | - |
Ubiquigent Ltd.
Ubiquigent Ltd. Miscellaneous Commercial ServicesCommercial Services Ubiquigent Ltd. develops reagents, kits, drug discovery assay development and compound profiling services to the academic and commercial life science research community worldwide. It focus; namely the ubiquitin, ubiquitin-like and integrated signalling systems. The company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery as well as with pharmaceutical and biotechnology company scientists undertaking ubiquitin system-focused drug discovery. Ubiquigent was founded by Jason Brown in 2009 and is headquartered in Dundee, the United Kingdom. | 12 ans |
Paul Barton Rodgers | M | - |
Ampika Ltd.
Ampika Ltd. Drugstore ChainsRetail Trade Ampika Ltd. discovers and develops drugs. It develops consumer products and prescription drugs from plant-based compounds. Its products includes cardiovascular protection, anti-infectives, diabetes, oncology, dermatological conditions and neurological. The company was founded by Francoise Barbira Freedman, Margaret Adey, Paul Rodgers and Jonathan Mark Treherne in May 2003 and is headquartered in Cambridge, the United Kingdom. | - |
Luca Anderlini | M | 66 |
University of Cambridge
| 17 ans |
Martin Roper | M | 61 |
University of Cambridge
| 5 ans |
Bojosi Otlhogile | M | - |
University of Cambridge
| 7 ans |
Paula Disberry | F | 56 |
University of Cambridge
| 5 ans |
Anthony G. Johnson | M | - |
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | - |
Trevor Thomas | M | - |
University of Cambridge
| 7 ans |
Mark Maybury | M | - |
University of Cambridge
| 5 ans |
Wing Hoy Tsang | M | 55 |
University of Cambridge
| 8 ans |
Ka-Pik So | F | - |
University of Cambridge
| 4 ans |
Gilberto Arias | M | - |
University of Cambridge
| 4 ans |
Chi Keung Lau | M | 69 |
University of Cambridge
| 5 ans |
Michael John Wilson | M | - |
University of Cambridge
| 8 ans |
Nicholas Taylor | M | 55 |
University of Cambridge
| 5 ans |
Gabrielle Walker | M | - |
University of Cambridge
| 7 ans |
John Simon Hunt | M | 61 |
University of Cambridge
| 4 ans |
Ram shenoy | M | - |
University of Cambridge
| 3 ans |
Julian Healy | M | 62 |
University of Cambridge
| 5 ans |
Alastair K. Livesey | M | 67 |
University of Cambridge
| 3 ans |
Tin Chee Ip | M | 62 |
University of Cambridge
| 6 ans |
Richard V. Penty | M | - |
University of Cambridge
| 8 ans |
R. Dominic King-Smith | M | - |
University of Cambridge
| 7 ans |
Ting Min Tan | F | 55 |
University of Cambridge
| 7 ans |
Cesare Zetti | M | 57 |
University of Cambridge
| 3 ans |
Jonathan Aberman | M | - |
University of Cambridge
| 8 ans |
Roy Merritt | M | 60 |
University of Cambridge
| 4 ans |
Oliver Boucher | M | - |
University of Cambridge
| 6 ans |
Wing Yan Lo | M | 63 |
University of Cambridge
| 3 ans |
Christopher A. Grew | M | - |
University of Cambridge
| 6 ans |
Mike Webster | M | - |
University of Cambridge
| 5 ans |
Philip Atkin | M | - |
University of Cambridge
| 3 ans |
Adrian Blumfield | M | - |
University of Cambridge
| 3 ans |
Chuan Thye Kho | M | 56 |
University of Cambridge
| 4 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Royaume-Uni | 51 | 51,00% |
Etats-Unis | 32 | 32,00% |
France | 13 | 13,00% |
Danemark | 4 | 4,00% |
Australie | 0 | -.--% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Jonathan Treherne
- Réseau Personnel